Effect of Pentoxifylline on Liver Regeneration After Right Lobe Donor Hepatectomy: A Randomized Control Trial

What this Trial Is About

Researchers are investigating the effect of Pentoxifylline on liver regeneration in live donors undergoing major liver surgery called right lobe donor hepatectomy. This study aims to analyze how Pentoxifylline supplementation affects anatomical liver growth, building on previous research showing its potential benefits in liver regeneration and protection after liver surgery. The trial is a randomized controlled trial conducted at a high-volume liver transplant center in India. Participants receive either an intravenous injection of Pentoxifylline at a dose of 1 mg/kg/hr dissolved in Plasma Lyte or 0.9% normal saline, starting 12 hours before surgery and continuing up to 72 hours after surgery, or intravenous fluid Plasmalyte as a comparator. The intervention period covers the perioperative phase around the surgery. During the study, participants will be monitored for liver volume regeneration two weeks after surgery, along with various blood markers related to liver function and regeneration measured up to two weeks post-operation. These include serum bilirubin, liver enzymes (AST, ALT, alkaline phosphatase, GGT), coagulation status (INR), growth factors, and inflammatory markers such as TNF-alpha, IL-6, and TGF-beta. Researchers will also observe any postoperative complications. The total follow-up includes assessments primarily on postoperative days 7 and 14.

To Study Effect of Injection Pentoxifylline on Liver Growth After Major Liver Surgery